WASHINGTON - Biotechnology and research-based pharmaceutical companies have reacted favorably to FDA's proposal to extend the marketing exclusivity period for newly approved products based on a single enantiomer of a previously approved racemate to five years from the current three-year period.

In comments filed with the agency, generic drug manufacturers predictably expressed opposition to the proposal, which could give manufacturers an additional two years of protection from generic competition.